{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:30:29Z","timestamp":1786717829678,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/2230-8210.179996","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T02:53:45Z","timestamp":1460343225000},"page":"372","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India"],"prefix":"10.4103","volume":"20","author":[{"given":"KM","family":"Prasanna Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanathan","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganapathi","family":"Bantwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Meininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.179996-1","first-page":"121","volume-title":"Prevention of type 2 diabetes and its complications in developing countries: A review","author":"Rawal","year":"2012","journal-title":"Int J Behav Med"},{"key":"key-10.4103\/2230-8210.179996-2","first-page":"137","volume-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"key-10.4103\/2230-8210.179996-3","first-page":"3022","volume-title":"Prevalence of diabetes and prediabetes (impaired fasting glucose and\/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study","author":"Anjana","year":"2011","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.179996-4","first-page":"1471","volume-title":"Burden of type 2 diabetes and its complications \u2013 The Indian scenario","author":"Ramachandran","year":"2002","journal-title":"Curr Sci"},{"key":"key-10.4103\/2230-8210.179996-5","first-page":"217","volume-title":"Epidemiology of type 2 diabetes: Indian scenario","author":"Mohan","year":"2007","journal-title":"Indian J Med Res","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5916","issn-type":"print"},{"key":"key-10.4103\/2230-8210.179996-6","first-page":"355","volume-title":"Chronic complications in newly diagnosed patients with type 2 diabetes mellitus in India","author":"Sosale","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.179996-7","first-page":"53","volume-title":"Diabetes in South Asians: Is the phenotype different?","author":"Unnikrishnan","year":"2014","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.179996-8","first-page":"1232","volume-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.179996-9","first-page":"294","volume-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-10","first-page":"163","volume-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study","author":"Stenl\u00f6f","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2230-8210.179996-11","doi-asserted-by":"crossref","unstructured":"Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64.","DOI":"10.2337\/dc13-2762"},{"key":"key-10.4103\/2230-8210.179996-12","first-page":"1016","volume-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-13","first-page":"372","volume-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-14","first-page":"941","volume-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.179996-15","first-page":"2582","volume-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.179996-16","first-page":"2508","volume-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.179996-17","first-page":"1267","volume-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/2230-8210.179996-18","first-page":"467","volume-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","author":"Forst","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-19","first-page":"463","volume-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-20","first-page":"72","volume-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial","author":"Bode","year":"1995","journal-title":"Hosp Pract ("},{"key":"key-10.4103\/2230-8210.179996-21","first-page":"e105638","volume-title":"Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes","author":"Sha","year":"2014","journal-title":"PLoS One"},{"key":"key-10.4103\/2230-8210.179996-22","first-page":"601","volume-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.179996-23","first-page":"E867","volume-title":"Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus","author":"Polidori","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.179996-24","first-page":"539","volume-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-25","doi-asserted-by":"crossref","unstructured":"Kumar KM, Mohan V, Sethi B, Gandhi P, Bantwal G, Xie J, et al. Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus from India. Poster Presented at: The 10th International Diabetes Federation Western Pacific Region (IDF-WPR) Congress; 21-24 November 2014; Suntec, Singapore.","DOI":"10.1016\/S0168-8227(14)70716-8"},{"key":"key-10.4103\/2230-8210.179996-26","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) \u2013 A randomized placebo-controlled trial. Am Heart J 2013;166:217-223.e11.","DOI":"10.1016\/j.ahj.2013.05.007"},{"key":"key-10.4103\/2230-8210.179996-27","first-page":"23","volume-title":"Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea","author":"Ji","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-28","first-page":"1136","volume-title":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study","author":"Inagaki","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-29","first-page":"1501","volume-title":"Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: A 24-week, randomized, double-blind, placebo-controlled, phase III study","author":"Inagaki","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/2230-8210.179996-30","first-page":"210","volume-title":"Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study","author":"Inagaki","year":"2015","journal-title":"J Diabetes Investig"},{"key":"key-10.4103\/2230-8210.179996-31","first-page":"64","volume-title":"Type 2 diabetes in East Asians: Similarities and differences with populations in Europe and the United States","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/2230-8210.179996-32","first-page":"S5","volume-title":"Distinguishing among incretin-based therapies.Pathophysiology of type 2 diabetes mellitus: Potential role of incretin-based therapies","author":"Campbell","year":"2010","journal-title":"J Fam Pract"},{"key":"key-10.4103\/2230-8210.179996-33","first-page":"106","volume-title":"Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea","author":"Mohan","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"key-10.4103\/2230-8210.179996-34","first-page":"737","volume-title":"Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus","author":"Pan","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-35","first-page":"268","volume-title":"Efficacy and safety of saxagliptin in drug-na\u00efve Asian patients with type 2 diabetes mellitus: A randomized controlled trial","author":"Pan","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"key-10.4103\/2230-8210.179996-36","first-page":"217","volume-title":"Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial","author":"Yang","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"key-10.4103\/2230-8210.179996-37","first-page":"227","volume-title":"The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes","author":"Yang","year":"2012","journal-title":"J Diabetes"},{"key":"key-10.4103\/2230-8210.179996-38","first-page":"891","volume-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.179996-39","doi-asserted-by":"crossref","unstructured":"Ji L, Ma J, Li H, Mansfield TA, T'joen CL, Iqbal N, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: A randomized, blinded, prospective phase III study. Clin Ther 2014;36:84-100.e9.","DOI":"10.1016\/j.clinthera.2013.11.002"},{"key":"key-10.4103\/2230-8210.179996-40","first-page":"432","volume-title":"Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: A phase II multicentre, randomized, double-blind, placebo-controlled trial","author":"Kaku","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.179996-41","first-page":"65","volume-title":"Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study","author":"Kaku","year":"2014","journal-title":"Cardiovasc Diabetol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:28:34Z","timestamp":1786714114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2230-8210.179996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"alternative-id":["179996"],"URL":"https:\/\/doi.org\/10.4103\/2230-8210.179996","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}